Loading...
•
Dec 31, 2023
Zymeworks Q4 2022 Earnings Report
Zymeworks reported its fourth quarter and full year 2022 financial results, highlighting significant revenue growth and a shift to net income, driven by strategic collaborations and a strengthened financial position.
Key Takeaways
Zymeworks Inc. reported a substantial increase in revenue for the fourth quarter and full year 2022, primarily due to a significant licensing agreement with Jazz Pharmaceuticals. The company achieved net income for the year, a significant improvement from a net loss in the previous year, and ended 2022 with a strong cash position, extending its cash runway through 2026.
Total revenue for the fourth quarter of 2022 was $402.493 million, a significant increase from $19.870 million in the same period last year.
The company reported net income of $309.431 million for Q4 2022, a substantial improvement from a net loss of $39.152 million in Q4 2021.
Basic EPS for Q4 2022 was $4.65, compared to -$0.76 in Q4 2021.
Zymeworks ended 2022 with $492.232 million in cash, cash equivalents, and short-term investments, with an expected cash runway through 2026.
Forward Guidance
Zymeworks expects to have cash resources to fund planned operations through at least the end of 2026, with a net operating cash burn for calendar year 2023 projected between $90 million and $120 million, including planned capital expenditures of approximately $15 million.
Positive Outlook
- Expected cash runway through 2026, potentially beyond, due to improved financial position and reduced cash burn rate.
- Continued advancement of zanidatamab with multiple upcoming clinical catalysts, including pivotal study data in 2024.
- IND filings for new preclinical product candidates ZW171 and ZW191 on track for 2024.
- Anticipated additional milestone payments from existing licensing agreements in 2023 and 2024.
- Plans to host a conference call in April 2023 to discuss preclinical product candidates and zanidatamab zovodotin data.
Challenges Ahead
- Research and development expenditures are expected to increase over time, subject to periodic fluctuations.
- Current challenging macroeconomic conditions may impact business operations.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...